Avelumab (MSB0010718C), an Anti-PD-L1 Antibody, Evaluated in a Phase Ib Trial as a First-Line Treatment for Patients with Metastatic NSCLC

被引：0

作者：

Verschraegen, Claire ^{[1
]}

Goel, Sanjay ^{[2
]}

Chen, Franklin ^{[3
]}

Spigel, David R. ^{[4
]}

Iannotti, Nicholas ^{[5
]}

Bajars, Marcis ^{[6
]}

Von Heydebreck, Anja ^{[7
]}

Kelly, Karen ^{[8
]}

机构：

[1] Univ Vermont, Ctr Canc, Div Hematol Oncol, Burlington, VT USA

[2] Montefiore Med Ctr, Bronx, NY 10467 USA

[3] Novant Hlth Oncol Specialists, Forsyth Reg Canc Ctr, Winston Salem, NC USA

[4] Tennessee Oncol Llc, Sarah Cannon Res Inst, North Nashville, TN USA

[5] Hematol Oncol Associates Treasure Coast, Port St Lucie, FL USA

[6] Emd Serono Inc, Global Res & Early Dev Immunooncol, Billerica, MA USA

[7] Merck Kgaa, R&D Global Biostat, Darmstadt, Germany

[8] Univ Calif Davis, Ctr Comprehens Canc, Sacramento, CA 95817 USA

来源：

关键词：

avelumab; NSCLC; PD-L1; MSB0010718C;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P3.01-084

引用

页码：S666 / S666

页数：1